AI Engines For more Details: Perplexity Kagi Labs You
Gastric Ulcer Prevention and Treatment: Misoprostol is commonly prescribed to prevent and treat gastric ulcers caused by long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen. It works by increasing the production of protective mucus in the stomach lining and reducing the secretion of stomach acid, thereby helping to prevent ulcers from forming or worsening.
Labor Induction: Misoprostol is used off-label for labor induction in pregnant women. It helps soften and dilate the cervix, leading to uterine contractions and initiation of labor. Misoprostol may be administered vaginally or orally under medical supervision to induce labor in cases where it is medically necessary to deliver the baby.
Medical Abortion: Misoprostol is also used in combination with mifepristone or methotrexate for medical abortion (termination of pregnancy). It causes uterine contractions and expulsion of the uterine contents, resulting in the termination of the pregnancy. Medical abortion with misoprostol is typically performed within the first trimester of pregnancy and requires close medical supervision.
Cervical Ripening: In addition to labor induction, misoprostol is used for cervical ripening (softening and dilation of the cervix) prior to certain gynecological procedures such as dilation and curettage (D&C), hysteroscopy, or placement of an intrauterine device (IUD). It helps facilitate the procedure by preparing the cervix for instrumentation.
Side Effects: Common side effects of misoprostol may include abdominal cramping, diarrhea, nausea, vomiting, and fever. These side effects are usually mild and transient, but some individuals may experience more pronounced symptoms requiring medical attention. In the context of medical abortion, misoprostol may also cause heavy bleeding and passage of tissue.
Contraindications: Misoprostol is contraindicated in pregnant women who are carrying a wanted pregnancy, as it can cause abortion. It should not be used by individuals with a history of uterine surgery or scar tissue, as it may increase the risk of uterine rupture. Misoprostol should also be used with caution in patients with a history of cardiovascular disease or inflammatory bowel disease.
Efficacy: The efficacy of misoprostol for gastric ulcer prevention and labor induction varies depending on the individual patient and the specific clinical scenario. It may be more effective when used in combination with other medications or interventions, such as proton pump inhibitors for gastric ulcer prevention or oxytocin for labor induction.
Off-label Use: Misoprostol is frequently used off-label for various indications, including cervical ripening, management of postpartum hemorrhage, treatment of incomplete abortion, and induction of abortion in cases of fetal demise or severe fetal anomalies. Off-label use should be guided by clinical evidence and professional guidelines.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| ADHD | 0.3 | 0.3 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.3 | 0 |
| Allergies | 0.2 | 0.2 | |
| Alzheimer's disease | 0.3 | 0.7 | -1.33 |
| Ankylosing spondylitis | 0.3 | 0.3 | |
| Anorexia Nervosa | 0.3 | 0.3 | 0 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | 0 |
| Asthma | 0.5 | 0.3 | 0.67 |
| Atrial fibrillation | 0.3 | 0.3 | 0 |
| Autism | 0.5 | 0.6 | -0.2 |
| Autoimmune Disease | 0.3 | 0.3 | |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| Biofilm | 0.3 | 0.3 | |
| Bipolar Disorder | 0.3 | 0.3 | |
| Brain Trauma | 0.3 | 0.3 | |
| Carcinoma | 0.6 | 0.6 | |
| Celiac Disease | 0.3 | 0.3 | 0 |
| Cerebral Palsy | 0.3 | 0.3 | |
| Chronic Fatigue Syndrome | 0.5 | 0.7 | -0.4 |
| Chronic Kidney Disease | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.5 | 0.3 | 0.67 |
| Chronic Urticaria (Hives) | 0.3 | 0.3 | |
| Coagulation / Micro clot triggering bacteria | 0.3 | 0.3 | 0 |
| Cognitive Function | 0.3 | 0.3 | 0 |
| Colorectal Cancer | 0.5 | 0.5 | |
| Coronary artery disease | 0.3 | 0.3 | |
| COVID-19 | 0.9 | 1.1 | -0.22 |
| Crohn's Disease | 0.6 | 0.6 | |
| deep vein thrombosis | 0.3 | -0.3 | |
| Denture Wearers Oral Shifts | 0.5 | 0.5 | |
| Depression | 0.9 | 0.3 | 2 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.3 | 0.5 | -0.67 |
| Endometriosis | 0.3 | 0.3 | |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 0.3 | 0.3 | |
| erectile dysfunction | 0.6 | 0.6 | |
| Fibromyalgia | 0.6 | 0.6 | |
| Functional constipation / chronic idiopathic constipation | 0.3 | 0.3 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | -0.3 | |
| Generalized anxiety disorder | 0.3 | 0.3 | 0 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.6 | 0.6 | |
| Graves' disease | 0.3 | -0.3 | |
| Gulf War Syndrome | 0.3 | 0.3 | |
| Halitosis | 0.3 | 0.3 | 0 |
| Hashimoto's thyroiditis | 0.3 | -0.3 | |
| Heart Failure | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| hyperglycemia | 0.2 | 0.2 | |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.3 | 0.6 | -1 |
| IgA nephropathy (IgAN) | 0.3 | 0.3 | |
| Inflammatory Bowel Disease | 1.2 | 0.7 | 0.71 |
| Insomnia | 0.5 | 0.3 | 0.67 |
| Irritable Bowel Syndrome | 0.3 | 0.3 | 0 |
| ischemic stroke | 0.3 | 0.3 | |
| Liver Cirrhosis | 0.8 | 0.6 | 0.33 |
| Long COVID | 1.1 | 0.3 | 2.67 |
| Lung Cancer | 0.3 | 0.3 | |
| Mast Cell Issues / mastitis | 0.3 | 0.3 | |
| ME/CFS with IBS | 0.5 | 0.5 | |
| ME/CFS without IBS | 0.3 | 0.3 | |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.3 | |
| Metabolic Syndrome | 1 | 0.6 | 0.67 |
| Mood Disorders | 0.8 | 0.3 | 1.67 |
| multiple chemical sensitivity [MCS] | 0.5 | 0.5 | |
| Multiple Sclerosis | 0.8 | 0.3 | 1.67 |
| myasthenia gravis | 0.3 | 0.3 | |
| Neuropathy (all types) | 0.3 | 0.3 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.9 | 0.9 | |
| Obesity | 0.6 | 0.5 | 0.2 |
| obsessive-compulsive disorder | 0.3 | 0.3 | 0 |
| Osteoarthritis | 0.9 | 0.3 | 2 |
| Osteoporosis | 0.3 | -0.3 | |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 0.8 | 0.9 | -0.13 |
| Polycystic ovary syndrome | 0.3 | 0.6 | -1 |
| primary biliary cholangitis | 0.3 | 0.3 | 0 |
| Primary sclerosing cholangitis | 0.3 | 0.3 | |
| Psoriasis | 0.3 | 0.3 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.6 | 0.6 | |
| Schizophrenia | 0.6 | 0.6 | |
| scoliosis | 0.3 | -0.3 | |
| Sjögren syndrome | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Systemic Lupus Erythematosus | 0.6 | 0.6 | |
| Tic Disorder | 0.3 | 0.3 | |
| Tourette syndrome | 0.3 | 0.3 | |
| Type 1 Diabetes | 0.6 | 0.3 | 1 |
| Type 2 Diabetes | 0.8 | 0.3 | 1.67 |
| Ulcerative colitis | 0.9 | 0.3 | 2 |
| Unhealthy Ageing | 0.8 | 0.8 | |
| Vitiligo | 0.3 | 0.3 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
